Navigation Links
NCC and Wyeth Donation to Assist Cancer Patients in Latin America
Date:1/14/2009

LIMA, Peru, Jan. 14 /PRNewswire/ -- The National Cancer Coalition (NCC) and Wyeth Pharmaceuticals (Wyeth) are pleased to announce a pilot program to assist cancer patients in Latin America with donations of Wyeth's cancer-related medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) (oprelvekin).

United States Ambassador Michael McKinley and the Peruvian Health Ministry participated in a hand-over event held at the Instituto Nacional de Enfermadades Neoplacias (INEN) in Lima, along with representatives from National Cancer Coalition, Wyeth Pharmaceuticals, INEN, and the Peruvian media. This donation to INEN, which is the largest public cancer hospital in Peru, consists of life-saving medicines valued at over $500,000.

Ambassador McKinley stated, "The event we are celebrating today is very important for several reasons. First, because this donation is the light of hope for many cancer patients in Peru who, due to the large quantity of medicines being donated today, will have access to life-saving treatment. In addition, this event is very special because it underscores the importance of public-private partnerships and the concrete gains that can be achieved with these partnerships to meet the critical health care needs of our citizens."

Eduardo Nieto, President, Wyeth Pharmaceuticals, Latin America, commented, "Wyeth is dedicated to aiding patients in need, and we are honored to be partnering with NCC in this initiative to provide oncology medicines to underserved patients in Peru."

"National Cancer Coalition is pleased that this new program with Wyeth Pharmaceuticals will lead to greater oncology resources for patients in the developing world. Through this donation, it is anticipated that over 100 Peruvian leukemia patients will be helped at INEN this year. NCC looks forward to expanding our medicine donation initiatives with Wyeth, as we jointly seek to help patients who would otherwise lack access to their required specialty medicines," stated Robert B. Landry, President of NCC. In the last five years, NCC has provided over $9 million worth of donated cancer medicines to INEN hospitals.

National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports cancer relief, research and educational programs throughout the world. The Coalition's international medical assistance program, termed NCC Cares, provides requested pharmaceuticals, medical equipment, and hospital supplies to public hospitals and local humanitarian organizations that help needy patients in over 40 developing countries around the world.

For additional information, please contact National Cancer Coalition at: 919-821-2182 or visit our website at http://www.nationalcancercoalition.org.


'/>"/>
SOURCE National Cancer Coalition
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
2. Wyeth to Present at the JP Morgan Healthcare Conference
3. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals
4. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
5. Wyeth Sets Webcast and Conference Call for 2008 Fourth Quarter and Full Year Earnings
6. Wyeth to Present at the Credit Suisse Healthcare Conference
7. The Senior Citizens Leagues Comments on U.S. Supreme Court Case Wyeth v. Levine
8. Wyeth v. Levine: Preemption and The Facts
9. Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
10. Wyeth Selected for 11th Consecutive Year as One of Working Mother Magazines 100 Best Companies for Working Mothers
11. Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... management program at Women’s Excellence will help patients lose weight and keep it ... The specialists at Women's Excellence will measure BMI, body fat composition, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  iCAD (Nasdaq: ICAD), ... solutions and radiation therapy for the early identification ... Tomo Detection received Premarket Approval (PMA) from the ... Detection is a first-of-its-kind, concurrent-read computer aided detection ... the latest innovation available on the PowerLook® Breast ...
(Date:3/27/2017)... 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced ... M. Bisaro as Impax,s President and Chief Executive ... March 27, 2017. Mr. Bisaro will succeed J. ... and Chief Executive Officer since December of 2016. ... pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global ...
(Date:3/27/2017)... March 27, 2017   Genprex, Inc. , a privately held, ... Pham , MD, the Company,s Chief Operating Officer, is scheduled to ... Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, ... York, NY ... BioCentury 24th Annual Future Leaders in Biotech Industry – ...
Breaking Medicine Technology: